


At 40 Years Old, the Orange Book Gets a Fresh Look as FDA Seeks Comments on Patent Listability

Feel Like DOE is Having a Rebirth in Life Science Cases? You’re Not Alone

Even If the Federal Circuit Could Award Attorney Fees for IPR Appeals, § 285 Does Not Permit It to Award Fees Incurred During the IPR

Update: Recent International Activity on IP in Response to COVID-19

New Treatments for COVID-19: Recent International Activity Relating to IP and Some Tools the US Already Has in Place

“Numerous Reasons” Support Finding Inequitable Conduct: Another Example of the Federal Circuit’s Current Approach to Inequitable Conduct
